JPMorgan Chase & Co. decreased its stake in shares of Xencor Inc (NASDAQ:XNCR) by 1.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 284,625 shares of the biopharmaceutical company’s stock after selling 4,875 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.61% of Xencor worth $6,552,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Emory University purchased a new stake in Xencor during the 2nd quarter worth about $1,491,000. Virginia Retirement Systems ET AL increased its holdings in Xencor by 10.0% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 76,200 shares of the biopharmaceutical company’s stock worth $1,747,000 after purchasing an additional 6,900 shares during the period. State Street Corp increased its holdings in Xencor by 11.1% during the 2nd quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock worth $23,295,000 after purchasing an additional 110,474 shares during the period. State of Wisconsin Investment Board purchased a new stake in Xencor during the 2nd quarter worth about $612,000. Finally, Vanguard Group Inc. increased its holdings in Xencor by 5.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock worth $35,913,000 after purchasing an additional 90,094 shares during the period. Institutional investors own 77.50% of the company’s stock.
Shares of Xencor Inc (NASDAQ:XNCR) opened at $22.50 on Friday. Xencor Inc has a 1 year low of $18.55 and a 1 year high of $28.64. The firm has a market capitalization of $1,070.00, a P/E ratio of -22.28 and a beta of 2.09.
Several equities research analysts have weighed in on the company. ValuEngine downgraded Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. BidaskClub downgraded Xencor from a “sell” rating to a “strong sell” rating in a report on Friday, December 15th. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a report on Saturday, November 11th. Piper Jaffray Companies reiterated a “buy” rating and issued a $35.00 price objective on shares of Xencor in a report on Sunday, November 12th. Finally, Cantor Fitzgerald initiated coverage on Xencor in a report on Wednesday, November 29th. They issued an “overweight” rating and a $33.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. Xencor has a consensus rating of “Hold” and a consensus price target of $30.80.
In related news, major shareholder John S. Stafford III acquired 150,000 shares of the firm’s stock in a transaction on Friday, October 27th. The stock was bought at an average cost of $19.81 per share, with a total value of $2,971,500.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder John S. Stafford III acquired 50,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were bought at an average cost of $19.58 per share, with a total value of $979,000.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 278,535 shares of company stock valued at $5,526,936 over the last ninety days. 4.14% of the stock is owned by insiders.
WARNING: This article was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://ledgergazette.com/2018/01/13/xencor-inc-xncr-position-lowered-by-jpmorgan-chase-co.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.